Zhi Qi

Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment

Ningshu Liu, Y. Zou, Zihan Xu, 2022, Nature Communications.

Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression

Benyi Li, Changlin Li, Wei Wei, 2020, Cellular Oncology.

Glutathione S-transferase M 1 polymorphism and bladder cancer risk : a meta-analysis involving 50 studies

Erjiang Zhao, Zhi Qi, Ruina Bai, 2017 .

Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by sequential intermittent anti-PI3Kα/β/δ and anti-PD-1 treatment

Hong Wu, Y. Zou, Zihan Xu, 2020, bioRxiv.

Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein

Benyi Li, Changlin Li, Shan Wang, 2022, Cell death & disease.

Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439

Hong Wu, Y. Zou, T. Shenoy, 2018, Molecular Cancer Therapeutics.